Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Exclusive Content A Fresh IPO That Long-Term Investors Shouldn't IgnoreAuthor: Jordan Chussler. First Published: 1/14/2026. 
Key Points - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. Even so, some recently public companies may merit consideration in buy-and-hold portfolios—particularly for investors willing to accept a bit more volatility. A widely followed Wall Street analyst is highlighting AES Corp (AES) as a stock to watch right now, based on signals from his proprietary Power Gauge system. The model tracks factors like momentum, financial strength, and institutional activity across thousands of U.S. stocks.
He breaks down the full reasoning in a short briefing, including why AES is showing unusual strength at this stage of the market. See the full analysis here One healthcare company that just went public could fit that profile. Last Year's IPO Success Stories Last year is a strong example of why newly public companies shouldn't be dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have benefited from an even larger early gain—nearly 359% before 30 days on the Nasdaq—but longer-term holders are still enjoying strong returns. Other debuts show that not all IPOs are unproven startups. Medical products and services provider Medline (NASDAQ: MDLN) publicly debuted in December 2025 but was founded in 1966 and already has a market cap above $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous bacon packages—waited 89 years before going public. Since its January 2025 IPO the stock is up nearly 5% and pays a dividend that yields 4.44% (about $1 per share annually), making it immediately interesting to income investors. After its IPO on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a developer of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a branch of nuclear medicine that uses radioactive drugs for both diagnosis and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals pair radioactive isotopes with targeting molecules that seek out specific cells (for example, cancer cells) to deliver localized doses of radiation. This targeted approach can reduce collateral damage to healthy tissue compared with some conventional radiation therapies. Industry consultancy Grand View Research estimated the global nuclear medicine market at nearly $18 billion in 2024 and forecasts it to reach almost $35 billion by 2030, a compound annual growth rate of about 10.16%. Grand View Research also notes that North America accounts for roughly 43% of the global nuclear medicine market, with the United States the dominant regional player—important context for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPO activity to rebound in 2026 after funding cuts by the Trump administration slowed healthcare-sector listings in 2025. Aktis, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and generated one of the largest recent raises for a biotech. The offering raised $318 million, and the company now has a market cap of roughly $3.34 billion. According to the company's prospectus, the executive team includes veterans of drug development, regulatory approval and commercialization; management members have helped bring 14 FDA-approved products to market. Specifically, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs that use proprietary targeting technology to attack solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not stop it from attracting major pharma interest. Eli Lilly (NYSE: LLY) anchored the IPO, purchasing $100 million in AKTS shares, according to Reuters. That investment builds on a 2024 partnership between the companies to develop tumor-targeting radiopharmaceuticals. As part of that earlier deal, Aktis received $60 million in cash and an equity investment from Lilly, with potential milestone payments that could exceed $1 billion. The significance of Lilly's backing is notable. At about $1.01 trillion, Eli Lilly is among the largest pharmaceutical companies by market cap, following a near-109% year-over-year jump in net income from 2023 to 2024. That trend is likely to draw attention when Lilly reports Q4 and full-year 2025 results on Feb. 5. Between its equity stake, the prior $60 million cash payment and the recent $100 million purchase of AKTS shares, Lilly now has a sizable financial interest in the biotech's success.
| 
